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Abstract
Background: Few studies have explored in depth the experiences of patients with advanced cancer who are
participating in clinical investigational medicinal product trials. However, integrated qualitative studies in such trials
are needed to enable a broader evaluation of patient experiences in the trial, with important ethical and practical
implications for the design and conduct of similar trials and treatment regimes in the future.
Methods: Ten participants were recruited from the control and intervention arms of FRAGMATIC: a non-placebo
trial for patients with advanced lung cancer. Participants were interviewed at up to three time points during their
time in the trial. Interviews were analysed using Interpretive Phenomenological Analysis.
Results: Patients were motivated to join the trial out of hope of medical benefit and altruism. Understanding of
randomisation was mixed and in some cases poor, as was appreciation of trial purpose and equipoise. The trial was
acceptable to and evaluated positively by most participants; participants receiving the intervention focused on the
potential treatment benefits they hoped they would receive, whilst participants in the control arm found alternative
reasons, such as altruism, personal fulfilment and positive attention, to commit to and perceive benefits from the
trial. However, whilst experiences were generally very positive, poor understanding, limited engagement with trial
information and focus on treatment benefits amongst some participants give cause for concern.
Conclusions: By exploring longitudinally the psychological, emotional and cognitive domains of trial participation,
we consider potential harms and benefits of participation in non-placebo trials amongst patients with advanced
lung cancer and identify several implications for future research with and care for patients with advanced cancer.
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Background
Although the use of qualitative methods in trials of com-
plex interventions in public health and health services
research is well established [1], this has been far less the
case in clinical trials of investigational medicinal products.
For example, in a recent systematic review of the use of
qualitative research in clinical trials, authors of only 5 of
296 papers (published between 2008 and 2010) were
found to have reported on clinical investigational medi-
cinal product (IMP) trials with patients with cancer [2].
Of the small amount of qualitative studies embedded in
cancer IMP or surgical trials, most have been focused on
exploring and finding ways of improving trial recruitment
processes [3–8]. Less common have been approaches
which have used qualitative methods to explore experi-
ences of participating in the trial in terms of patient well-
being and quality-of-life outcomes [9]. In trials of cancer
treatments, the primary endpoint is often survival, with
secondary endpoints such as quality of life measurements.
Embedded qualitative studies in clinical trials allow a
much more in-depth investigation of participants’ expe-
riences and perspectives than can be captured in these
kinds of structured questionnaires [9], and they are
necessary for capturing the wider benefits or harms
that trial participation may bring to patients, including
psychological and emotional impacts. This means con-
sidering patient understandings, expectations and moti-
vations; how patients experience the intervention itself;
and what else people get out of trials if not direct med-
ical benefits. Such findings can be used to help improve
the design and delivery of future trials, treatments and
services, or, as is the case in one of our current studies,
they can also be presented in real time to inform trials
which are on-going [10].
Research has shown how patients with cancer typically
seek therapeutic benefit from research participation, al-
though they may also be motivated by altruism [9, 11–14].
Joining a trial can also be an important means of preserv-
ing hope [11, 13, 14]. Whilst maintaining hope is clearly
important for patients with cancer, there is also concern
over the potential for ‘unrealistic optimism’ [13] and
‘therapeutic misconception’. This refers to situations in
which patients can confuse their participation in clin-
ical trials (which are justified on the basis of ‘equipoise’
and clinical uncertainty over best treatment options)
with personalized medical care and presumed medical
benefit [12, 15]. This in turn obstructs fully informed
consent to participate in research [12], making patients
vulnerable as research participants, at risk of making
potentially poor decisions [13, 16] and likely to experi-
ence profound disappointment and loss of hope if allo-
cated to the control arm [17, 18]. Research into how
patients with cancer understand study information has
similarly shown that patients focus on information
about disease and treatment at the expense of informa-
tion about the research, such as risks, side effects or
the purpose of the trial [19]. A number of qualitative
studies have also highlighted patient confusion and
misunderstanding related to key trial principles such as
randomisation and equipoise, along with difficulties
experienced by trial staff attempting to convey this
complex information [3–7, 17].
In addition to problematic communication practices,
the contextualised, experiential nature of patient know-
ledge and decision-making has been shown to further
undermine the acceptability of trial equipoise amongst
patients [8, 20, 21]. Research has demonstrated how
patients judge treatment outcomes subjectively on the
basis of their personal circumstances and experiences;
they assign their own meanings to trial outcomes and
may develop preferences based on a wider or different
set of concerns than those reflected in clinical outcomes
[8, 20, 21]. High levels of patient trust in and expecta-
tions of their clinical team also appear to obstruct
patient understanding and informed consent. Research
into how participants engage with study information has
demonstrated that some patients invest so much confi-
dence in their health professionals that they see less of a
need to understand study information in any detail [19],
or they may perceive an urgent need to act swiftly and
take decisive action, without fully engaging [22]. Studies
exploring reasons for non-consent to enter trials and the
acceptability of randomisation have similarly pointed to
the contradiction between participant expectations for
clinician direction and involvement in their treatment
decisions and principles of equipoise and clinical uncer-
tainty [3–8, 18]. Qualitative investigation is thus needed to
understand why patients choose to take part in clinical
trials, their understanding of important trial processes and
principles, and whether their reasoning for participation
can be considered to be indicative of informed consent.
Qualitative research also has a role in exploration of
what effects trial participation have on patient well-being
and quality of life. It is increasingly recognized that clinical
trials have more complex effects than those caused by the
treatment regime, and these have been investigated in
research into ‘trial effects’ [23]. On one hand, trial partici-
pation might make patients feel more useful or better sup-
ported (i.e., involve psychologically mediated effects), or
trial clinicians might become better informed or more
careful (because they feel under observation or are re-
quired to follow a carefully researched protocol), resulting
in improved outcomes. On the other hand, if patients find
the consent process stressful or if it results in loss of faith
in clinicians or treatments, then outcomes could be wors-
ened [23]. Some effects may also relate to the communica-
tion and relationships between patients and professionals,
changes in patients’ understanding of the meaning and
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cause of their symptoms, and the patient’s own activities
[24]. It is argued that in these situations people often
experience a wider range of changes than the more typical
biomedical, psychological or quality-of-life outcomes,
which suggests the significance of contextual factors as
well as the process of healing [24].
The researchers in the QualFRAG study explored longi-
tudinally the experiences of participants of a non-placebo
trial called FRAGMATIC, which has recently been reported
[25]. FRAGMATIC was a randomised phase III clinical trial
investigating the impact of injecting daily dalteparin (a low-
molecular-weight heparin) on overall survival in patients
with lung cancer. Intervention and control participants
were typically receiving standard chemotherapy treat-
ment, and intervention participants were randomly al-
located to also receive the daily injections. Participants
were informed of their trial arm allocation immediately
after randomisation had taken place, usually by one of
the trial research nurses. The trial opened to recruit-
ment in 2006 and closed in December 2011 once its
recruitment target of 2200 patients was reached. The
full trial protocol is available online [26].
The broad inclusion criteria and pragmatic study design
of FRAGMATIC allowed for the inclusion of patients with
advanced cancer; approximately 40 % of participants were
expected to have advanced cancer and palliative care
needs at trial entry. The advanced disease status of this
patient group and the non-placebo trial design add the
following more specific reasons for in-depth, qualitative
investigation of patient perspectives and experiences in
this and other similar studies. On the one hand, the poor
prognosis of patients with advanced lung cancer might
enhance their ‘vulnerability’ as research participants, their
risk of distress should they not receive their preferred
treatment, or their risk for other possible harms con-
nected with the trial or intervention (e.g., daily, sustained
injections). Equally, however, it is important that patients
with advanced disease be given the opportunity to take
part in research and that ‘gatekeeping’ based on assump-
tions of vulnerability does not undermine these opportun-
ities, as has often been the case [27]. Empirical research is
therefore needed which can illuminate the ‘whole-trial’
experiences of patients with different types of advanced
disease who are taking part in different types of trials. As
far as we are aware, no similar study has been carried out
with this patient-participant group in a non-placebo
clinical IMP trial.
The QualFRAG study opened during the last year of the
FRAGMATIC trial. The study was aimed at exploring the
experiences and perceptions of trial participants, with a
particular focus on the following:
1. The psychological impact of participation in a
clinical trial for patients with advanced lung cancer
in both intervention and control arms, with
particular emphasis on equipoise
2. The acceptability of long-term dalteparin as a therapy
in advanced lung cancer (intervention arm)
3. The impact of clinical trial monitoring processes in
terms of a positive attention effect and the
implications for service modelling
4. How patients prioritise and manage their symptom
burden over time
In this paper, we report key themes from the QualFRAG
study, focusing specifically on patient motivations, under-
standing and experiences of participating in the FRAG-
MATIC trial. Implications are identified for the future
design and conduct of trials with patients with advanced
cancer, as well as for the routine care of such patients, in-
cluding the potential use of daily dalteparin injections.
Themes relating to symptoms, side effects, quality of life
and patient coping will be reported separately in forth-
coming publications.
Methods
After the study received ethical approval from South
East Wales Research Ethics Committee (11/WA/0118), a
total of ten participants (one female, nine male) were
recruited from three sites in South Wales that were par-
ticipating in the trial. Eligible patients were approached
by their trial research nurses between September 2011
and December 2011. Recruitment to the QualFRAG
study ceased once the FRAGMATIC trial closed to
recruitment in December 2011. With the exception of
two patients (one of whom was never given study infor-
mation due to deterioration in condition), all eligible
patients at these sites entered into the study. We aimed
to interview participants three times, within 18 weeks
of joining the trial, 6 weeks after the first interview, and
6–8 weeks after the second interview. These time
frames were chosen to maximise our pool of eligible
patients in the first instance, with follow-up intervals
designed to capture change whilst minimising attrition.
The final number of recruited patients is shown in
Table 1, as are numbers per round of interviews. The
high rate of attrition, typical of palliative care research
[28], was due to deterioration and in some cases death.
With the exception of one patient who was interviewed
in the clinic, all other patients were interviewed at home,
Table 1 Recruitment and attrition figures
Interview 1 Interview 2 Interview 3 Total
interviews
Control group (CG) 6 4 3 13
Intervention group (IG) 4 2 1 7
10 6 4 20
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which is considered the most appropriate setting for this
patient group [29]. Several patients also had companions
present during the interviews, which, given the illness
status and potential vulnerability of these patients, was
also considered appropriate [29]. Unfortunately, because
consent was not taken from these participants, we were
unable to directly use their data, although their comments
provided useful context for the interpretation of patient
talk. During these interviews, interviewers took steps to
try to maximise patient involvement in the interview, such
as turning slightly to face the patient and verification of
comments made by companions [29]. Interviews were
carried out by two female researchers (EH and ME) who
were previously unknown to participants. They did not
have clinical backgrounds, although they had some prior
experience of interviewing patients or family members
affected by advanced illness and have doctoral degrees in
public health and health care research. A topic guide was
used which covered motivations for joining the trial,
understanding of trial processes and experiences with
symptoms, side effects and quality of life (summarised in
Table 2). The topic guide was informed by the findings of
a previous sub-study [9], the clinical experience of the
Principal Investigator, our study research questions and
methodological preference for an interview structure
which encourages participants to talk freely and develop
their own stories about the trial and illness and treatment
journeys more broadly. The researchers took written
informed consent before the start of the first interview,
which included consent to publish anonymised extracts
from participant transcripts. Interviews lasted between 15
minutes and 1 h. The interviews were digitally recorded,
transcribed verbatim and fully anonymised.
The analytic framework for this qualitative sub-study
was based on Interpretative Phenomenological Analysis
(IPA) [30]. IPA was chosen for this study because it
enables in- depth exploration of the lived experiences of
participants with the aim of understanding the meaning
that events has for participants based on their subjective
accounts [31]. IPA is interpretative in the sense that the
researcher’s conceptions and experience, as brought to
the analysis, are also recognized. IPA is based on an idio-
graphic approach beginning with a single case as a basis
upon which to develop more general categories developed
in a detailed case-by-case analysis. The nature of this
approach means that small sample sizes are preferred, and
homogeneous groups are purposively selected according
to important variables [32]. In this study, our groups were
defined by whether participants were control or interven-
tion participants, with a target sample size of 6 to 10 par-
ticipants per group (12 to 20 in total). Two researchers
(EH and ME) analysed the transcripts for themes fol-
lowing this methodology. Results were verified by the
research team by independent review of a selection of
transcripts.
Results
In this section, we present key themes on patient moti-
vations for joining the trial, understanding and accept-
ance of randomisation, equipoise and the acceptability of
intervention and control arms, engaging with trial infor-
mation, and the added benefits of trials.
Table 2 Summary of interview topics
Interview 1 topics Interviews 2 and 3 topics
Joining the trial
• Reasons for joining the trial
• Understanding of trial purpose, equipoise
and different trial arms
• Preferences for and responses to trial arm allocation
• Understanding of and views on randomisation
• Experience of receiving and accessing information
on the trial
Participating in the trial
• IG: Experiences of daily injections
(administering injections, side effects, support, continuation)
• CG: Views on daily injections
• Experience of attending clinics
• Experience with and views on data collection processes
• Perceived benefits or disadvantages of being on the trial
and suggestions for improvement
Treatment experiences and quality of life
• Length of time receiving treatment (e.g., chemotherapy)
• Understanding of treatment(s)
• Responses to treatment(s) (side effects and symptom management)
• Accessing information and support
• Impact of illness and treatments on quality of life
(daily activities, hobbies, social and family life)
Symptom burden, management and quality of life
• Symptoms experienced
• Symptom management and coping
• Accessing support and information
• Impact on quality of life
• Responses to chemotherapy/other treatment
• Experiences of blood clots
Experiences of injecting (IG)
• Administering injections and adherence
• Side effects and effects on daily life
• Views on continuing with and/or stopping injections
Other health care and trial experiences
• Experience of receiving information on treatment and illness progression
• Experiences of visiting clinic and accessing health care support
• Contact with research nurse and experiences of trial-related
appointments and information
End of study reflections (interview 3)
• Views on trial arm status at time of interview (compared with at start of trial)
•Perceived changes in symptoms and side effects over course of illness
• Differences between expectations of and experiences with treatment
• General reflections on experiences of participating in the trial and
views on participating in medical research
CG, control group; IG, intervention group
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Motivations for joining the trial
Intervention participants
Participants were asked about what motivated them to
join a research trial. Participants in the intervention
group expressed more egocentric motives than the con-
trol participants, as their main reason was to potentially
benefit from injecting dalteparin.
To help, to help me so I haven’t got the clots to stop
the spread of the cancer… that’s what I had it for.
[I1, interview 1]
Although one participant was mindful that the treatment
could benefit others in the future and saw ‘for humanity’ as
a reason to participate in research, his main concern was
for his own benefit.
So I thought, well, if it prevents blood clots, you know,
it’ll, for my benefit.… Obviously, for future benefit,
basically selfish, for myself, you know. [I3, interview 1]
For some participants this hope of treatment benefit
seemed influenced by suggestions from a health profes-
sional that there had been some success with the injections
so far. Several participants were willing to try anything that
was suggested to help them, implying a degree of desper-
ation and potential vulnerability, especially for the patient
who reported having little understanding of how the treat-
ment worked.
Well, obviously, medically, um, they did point out that
there has been some success with it…. And that was the
reason that I went on to it. Anything that can help me in
my present situation…, I’ll go along with. [I4, interview 1]
I didn’t really understand it; I just thought it’d help,
you know, if they were suggesting it, it would help with
the treatment. [I2, interview 1]
Other participants in the intervention group felt
obliged to try what was available to them on the grounds
that it might work, rather than have nothing.
Well, no, I’d rather have something that might prevent
it rather than have nothing, you know. Half a defence
is better than no defence. So, that’s what I thought, I
thought, well, uh, well it mightn’t, but then again if it
does. [I3, interview 1]
Control participants
Most participants in the control group presented more
altruistic motives for taking part in the trial. Their main
reasons for taking part were to contribute to cancer
research that might help other patients in the future.
These participants seemed to appreciate the value of
research for advancing treatments, and there was a sense
that participating in research was the right thing to do.
The participant below had accepted that his condition
was terminal and that the treatment would not cure
him, but he wanted to take part in the research to help
others.
What I’ve got is going to kill me anyway. There’s no
cure. It might give me time but that’s about all…. If
something can be done to help people in the future,
then surely that’s got to be a worthwhile thing when
it’s not taking an awful lot of time and it doesn’t take,
well, it doesn’t take anything [C3, interview 1]
Another of the control participants expressed a par-
ticular interest in participating in research and partici-
pated in more than one study. He valued the
information that is generated from research, was inter-
ested in the outcomes of research and had formed a
detailed understanding of how this particular treatment
worked. Participating in research also provided him with
a role, with activities to pass the time and help alleviate
the boredom, which he experienced after having to give
up work when he became ill. He found being a research
participant ‘fun’ and appreciated the attention from re-
search staff.
Yeah, yeah, I mean, it’s something to do, you know; it’s
good fun, it breaks things up. Life gets a bit boring when
you are stuck like this, you know. [C4, interview 1]
Understanding and acceptance of randomisation
Some participants understood randomisation. Control par-
ticipants spoke more on how they felt about being allocated
to their trial arm, compared with intervention participants,
who reported little more than feeling ‘pleased’ to be
getting the injections. Most of the participants who
understood the randomisation process were accepting
of the outcome on the basis that it was perceived as a
fair method of allocation.
I didn’t matter to me ’cause, as the nurse said to me,
they pick the names out the hat. [C5, interview 1]
Control participants appeared more reflective and had
attempted to make sense of the process and outcome of
randomisation and, with the exception of one patient,
were accepting of being allocated to the control arm.
The exception, by contrast, was so disappointed and
angered by the outcome that he withdrew from the trial
shortly after we interviewed him and did not participate
Harrop et al. Trials  (2016) 17:329 Page 5 of 12
in any further interviews. Although he understood the
principle of randomisation, he felt that his expectations
had been raised and his time wasted. He considered that
randomisation could have taken place before he was
given all of the information to read and made to travel a
distance to the hospital.
Like I say, difficult parking and all the rest of it, I took
part in so much as went along with all that was asked
me and filled forms in about this, that, the next thing,
uh, and I was there a couple of hours, and then they
start the random thing going, um, and I wasn’t chosen,
but I think if they could have pushed my name in
before and I was chosen and then asked me to go
down that would, I mean, well, as far as I was
concerned, it was a waste of time. [C2, interview 1]
Other patients clearly misunderstood the selection
process. Several patients thought that a medical decision
had been made about which arm they should be in based
on some kind of clinical assessment of their condition,
in one case following the results of a blood test and in
the example below by somebody not known to the
patient to safeguard against potential favouritism.
Well, it’s someone who doesn’t know you doing it. So
it’s not favouritism: ‘Oh yeah, that’s a friend of mine,
put him on it, like so’; so, yeah, it’s cuddling up, you
know. It’s just that nobody knows you; um, they make
a decision on the facts that they are given, and that’s
it. [I3, interview 1]
One participant not only misunderstood how he had
been allocated to the intervention arm but also seemed
unsure which arm he was even in, despite the ‘un-
blinded’, non-placebo design of the trial. Although he
was receiving the injections, he was unsure whether
these contained the ‘real stuff ’ as opposed to a placebo
treatment.
Well, I didn’t understand if it’s a trial…. Am I on it?
Or am I not on it? Is it the real stuff I am taking? Or
is it not the real stuff? [I2, interview 1]
Equipoise and acceptability of intervention arm
Most intervention participants understood that they
were taking part in a trial but seemed to focus more on
potential treatment benefits than on the nature of the
trial being to investigate a medicinal product. As such,
there was sometimes little or no understanding or con-
sideration of the unknown and potentially equal risks
and benefits of participating in the trial, and the
principle of equipoise. For example, some participants
felt that they should try all available treatment and that
‘something was better than nothing’. This motivation
may have influenced a cognitive bias towards the po-
tential benefit of treatment, which seemed to dominate
much of the talk about the trial amongst intervention
participants, several of whom emphasised potential
anti-cancer, curative effects of the treatment.
But apparently it could help shrink the cancers as
well…. That’s what they are hoping for. [I3, interview 1]
The focus on treatment benefit was similarly evident
in the ways in which intervention participants felt about
their injection regime. Although some participants did
not like injections, and most participants experienced
mild discomfort and pain as well as bruising around the
site of the injection, they tolerated daily injections
because of the potential benefits that they might get
from treatment.
I must be a bit of a masochist really, ’cause I hate
needles.… Because normally, even on television, you
see a medical programme and you see them
injecting…. I look away…. Yeah, and then I got to do it
myself. It’s for a purpose. [I3, interview 1]
A couple of patients found injecting a disadvantage of
being in the trial and expressed a preference to take a
pill if one were available, but again were prepared to
continue with the regime.
No, you know, I wish I could take a pill rather than
inject.… That’s the only thing. But obviously that’s not
probably practical…. So, as I say, it is as it is, and, uh,
I go along with it. [I4, interview 1]
In the later interviews, participants continued to tolerate
injecting, despite continuing discomfort, on the grounds
that it is ‘doing me good’.
I: Um, and how do you sort of feel about carrying on
injecting for the rest of the trial?
P: Alright, yeah.
I: You feel happy doing that?
P: As long as it’s doing me good, I don’t care. [I1,
interview 2]
For intervention patients, therefore, the perceived ben-
efits of the treatment seemed to outweigh the negative
side effects (bruising, pain and discomfort).
Equipoise and acceptability of control arm
Amongst control participants, there was also little ap-
preciation of clinical equipoise, with the exception of the
one patient (C4) who was well informed about the trial.
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This patient was ambivalent about being allocated to the
control arm or, to use his own words, felt ‘ambidex-
trous’. This ambivalence seemed to reflect an under-
standing that it is not known whether the injections
would give him a better outcome, and an appreciation of
the principle of clinical equipoise.
So, it was all straightforward, and as I said on
reflection at the time, I thought, well, maybe it’s a
good thing, bad thing, as I say…. I was, was I bit
ambidextrous at that point, you know, because we
didn’t really know whether it was sort of good, bad,
indifferent or what, you know. [C4, interview 1]
This participant had carried out his own Internet-
based research on the treatment and seemed to over-
estimate the risks of injecting by thinking that his risk
of cancer spreading may have been increased by the
drug.
The thing with the FRAGMIN is that, uh, the basic
idea was if you thin the blood up a bit, then the
chemo itself can access the tumour a lot easier. Uh,
the flip side of that, of course, is that if you thin the
blood up the chemo cells, uh, the tumour cells can also
travel around a bit easier. So it’s, it’s a doubled-edged
thing, is’n it? [C4, interview 1]
Some control participants were able also to see a posi-
tive side to the control arm: that they would not have to
administer daily injections. Although these participants
were prepared to go into the intervention arm and rec-
ognized the potential benefits of the injections, they
were also relieved that they did not have to inject, which
may have helped them accept their allocation. Whilst
not necessarily suggestive of clinical equipoise, by recog-
nizing the day-to-day negatives of the intervention arm,
they were able to balance out and accept their position.
So, like I say, I didn’t mind, don’t fancy having the
needle stuck in me every day. [C6, interview 1]
Only one patient dropped out of the trial as a re-
sponse to being randomised, following his allocation to
the control arm (C2). For this participant, there was a
different set of perceived costs and benefits associated
with participation. First, unlike the other control par-
ticipants, he displayed little appreciation of the value
of medical trials and hence perceived few benefits from
either a personal or wider public perspective. He had
also had some less than positive experiences in his
medical care and thus seemed less bound by the feel-
ings of reciprocity, dependency or trust expressed by
other participants.
The things that have annoyed me so far is you go to the
[name of principal hospital in city 3], you’ve got to be
there for eight o’clock in the morning, they got no bed for
you. So they can’t do anything until they have found a
bed for you, and I’ve been there from eight until half
past one, um, just hanging around. [C2, interview 1]
This patient also understood there to be greater costs
to trial participation. The patient had recently learned
that he could be treated with surgery instead of chemo-
therapy, which meant that he would need to make add-
itional non-treatment-related visits to the hospital to
fulfil his role as a trial participant. Adding to this, the
patient also lived a considerable distance from the hos-
pital, and it seems he incurred considerable expense and
inconvenience every time he attended an appointment,
some of which he also felt to have been unnecessary or
badly managed.
Engaging with trial information
Many participants did not fully engage with the trial infor-
mation prior to consenting to take part, no doubt explain-
ing some of the limited understanding described above.
Trial information was given at a time when patients had a
lot of information to take in about their diagnosis and
treatment. One participant felt overloaded with informa-
tion from a number of different health professionals at a
difficult and emotional time. Information about the trial
added to both his information and stress burden.
It was almost at the time I was just starting chemo, so
I had a load of information from the lung nurse, from
the doctor… the specialist, uh, which quite honestly
was almost an overload. Then I had this trial, which is
another load of information, and it’s quite a bit of an
overload when your mind is in [turmoil anyway]. [C3,
interview 1]
This patient’s response to ‘information overload’ was
thus to ‘switch off ’ or disengage. He was cautious about
focusing on ‘bad things’ if exposed to too much informa-
tion; his preference was for balanced information from a
health professional.
You can have too much information, and then you sit
down and you only hear the bad things. But if you get
the balance, as I call it, if they give you the balance, I
don’t think there’s any, you need anything else. You
don’t need to know the terminology and all that,
because when you look it up on the Internet, it’s
frightening. [C3, interview 1]
Most participants in the intervention group also chose
not to engage in any depth with the written information
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about the trial, preferring only to be informed of the
‘basics’. This participant reported not to have read the
trial information at all, relying only on the information
given by the research nurse. His focus was on simply
trying something that ‘might help’:
P: Yeah, I got all the information sheets, but reading
them [laughs]….
I: So you didn’t read them, you just went with what they
said, basically.
P: Yeah, if they are offering you something that they say
might help, you have got to try everything you know. [I2,
interview 1]
Added benefits of trial participation
In later interviews, several patients reflected on some of
the benefits that they had experienced from taking part.
As described above, many patients expressed altruistic
motives for participation, and one of these described
what could be considered a ‘feel-good’ factor which he
gained from participation, particularly given the minimal
commitment needed.
No trial ever has a negative, negativity. It always has
a positive; there’s always something positive that comes
out of it, even if it is only to say, ‘We don’t want to go
up that route’. So, so I have no problems. I mean, I
think I’m on three or four trials at the moment, yeah.
[C3, interview 3]
Some patients also perceived benefits from the additional
contact trials gave with medical staff, as well as the personal
qualities of these staff.
They’ve all been interesting. I’ve met some lovely,
interesting people.… If they came to me for any other
trials, I would partake. [C3, interview 3]
Well, I think being part of the trial, you’re looked at
better than if I wasn’t on the trial. You know, you’re
being watched more, you know, and so, and because
you see the research nurse. Otherwise, you are living
on your own and you never see anyone. At least they
are keep[ing] tabs on you. [C5, interview 3]
The importance of patients’ relationships and inter-
actions with their health professionals was similarly
highlighted in the favourable descriptions participants
gave of the friendly clinic environment.
It’s laid-back; it’s, it’s like home from home. It’s, there’s no
‘oh you’re the patient, we’re the experts’. [I3, interview 1]
Discussion
The reported findings derived from this qualitative sub-
study complement the results of the main FRAGMATIC
trial and contribute to the wider literature on clinical trials
with patients with advanced cancer. By exploring longitu-
dinally the psychological, emotional and cognitive domains
of trial participation, this paper provides a broader assess-
ment of potential harms and benefits of participation in
non-placebo trials amongst patients with advanced lung
cancer, with important ethical and practical implications for
the design and conduct of similar trials in the future.
This research enabled an in-depth exploration of
what it meant to patients to be participating in the trial.
This is important, as there may be negative psycho-
logical and emotional consequences of allocation to the
control arm in non-placebo trials, such as disappoint-
ment and hopelessness. Equally, however, patients may
experience positive psychological outcomes of taking
part. Patients in this study gave a number of reasons
for deciding to join the FRAGMATIC trial, which
included hope of medical benefit, trying everything,
interest in fulfilling a role as a research participant and
altruism. The most dominant of these, however, seemed
to be altruism amongst control participants and hope
of medical benefit amongst intervention participants.
Previous research has identified the motivating role of
both of these types of beliefs, although most suggests
hope of benefit to be primary [9, 11, 13, 14, 19].
At one level, our findings could be interpreted to mean
that different types of people have different reasons for
joining trials. However, the fact that the difference occurs
between our two groups suggests that the allocation
process and outcomes are likely factors. Participants were
not interviewed until after they had been randomized,
which would have influenced how they accounted for their
status as control or intervention participants. Control par-
ticipants may also have experienced more treatment-
oriented motives upon consenting to be randomized, but
following randomisation necessarily engaged in a process
of rationalisation [17] as they reappraised and considered
a wider range of reasons for participating than had they
been randomized to receive the extra treatment. Following
this, there was more explicit discussion and reflexivity
amongst control participants on how they reacted to being
allocated to the control group, as they attempted to make
sense of the process and outcome of randomisation.
In this study, it might therefore have been the process of
allocation to control which brought out altruistic and
other secondary motives amongst control participants,
who needed to find alternative rationales for participation
to enable acceptance of the trial and reduce feelings of dis-
appointment. As highlighted elsewhere, a perception of
randomisation as a ‘fair’ method of allocation supported
acceptance of the control arm, while an appreciation of
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the value of clinical trials enabled patients to experi-
ence their participation as meaningful [33]. Therefore,
although altruistic expressions featured more strongly
in the talk of our participants than in other studies on
the motivations or attitudes of patients with cancer
[11, 13, 19], this could be explained by the timing of
our post-randomisation interviews, against the pre-
trial timing of interviews in these other studies. In this
respect, these findings could support previous observa-
tions that altruism has a secondary motivating role to
trial participation, behind hope of medical benefit [13],
but adds to this the observation that in non-placebo
trials altruism may become primary amongst control
participants once randomisation has taken place.
In terms of weighing harms and benefits, these findings
suggest that intervention participants found daily injec-
tions tolerable (experiencing relatively minor physical side
effects) and derived hope from their allocation outcome.
Control participants (although likely disappointed at first)
were also able to find alternative rationales or benefits for
taking part, which helped them to accept and feel posi-
tively about their status in the trial. Whilst non-placebo
trials in this population group will always be contentious,
the nature of the intervention arm (daily injecting) meant
that this design was perhaps easier to accept for control
patients than had the intervention been less ‘invasive’. The
fact that the intervention arm was a ‘supplementary’ treat-
ment (given on top of the courses of chemotherapy given
to all patients) may also have increased the acceptability of
the trial for control participants. Some patients also de-
scribed additional benefits of trial participation in terms of
‘feeling good’ from helping others and perceived additional
contact with supportive clinical staff. Many were highly
appreciative of the friendly clinic environment, which
seemed to exceed their expectations, helped them to feel
valued as individuals and in some cases to ‘look forward’
to their time at clinic. This adds to the literature on ‘trial
effects’ by helping to explain how trials can have effects
which go beyond those of the treatment, for reasons such
as patients ‘feeling useful’, better supported and developing
positive relationships [23, 24].
However, whilst these findings suggest psychological,
emotional and social benefits for trial participants, when
we consider ‘cognitive’ domains, some negative issues are
identified. As in previous studies, a number of participants
had misunderstood the process of random selection [3–7]
and in some cases perceived treatment allocation based
on clinical assessment [17]. Amongst the majority of pa-
tients, there was also little consideration of the unknown
and potentially equal risks and benefits of participating in
the trial [17]. This was underpinned by a view that ‘some-
thing was better than nothing’ and a possible cognitive
bias towards the potential benefit of treatment, which in
some cases appears to have been influenced by comments
made by clinical staff. These beliefs provided the basis for
intervention participants’ acceptance and adherence to
their injection regime and could be considered indicative
of ‘therapeutic misconception’ [12]. This raises ethical
questions over the extent of ‘informed’ consent and the
potential vulnerability of these patients as research partici-
pants [11, 13, 16]. It also clearly raises questions over how
study information was presented to participants (including
whether participant understanding was checked at the
time of consent) and how it might be improved for future
trials, as has been accomplished in other cancer trials with
embedded qualitative designs [3, 7].
What these examples also demonstrate, however, is the
importance of contextualizing patient knowledge, (mis)un-
derstandings and related decision-making [8, 20, 21, 34].
Studies of ‘non-consenters’ into trials have demonstrated
reasonable understanding of randomisation but violated
expectations of direction and input from their clinicians as
factors undermining trial recruitment [3–8]. In this study,
however, it seems that some patients misunderstood ran-
dom selection and trial equipoise because of the expecta-
tions that they had of their physicians to use their expertise
to make treatment decisions that were personal to them,
and had entered the trial on that basis. This belief was simi-
larly apparent in how patients approached the study infor-
mation, with many describing feeling ‘overloaded’ and a
preference to instead take direction from their trusted
health professionals [19, 34, 35, 36, 37]. This suggests the
need to go beyond overly cognitive or ‘rational choice’
models of informed consent, which assume a process of
calculated assessment of medical and/or scientific informa-
tion, and give due consideration to the influences of rela-
tionships of trust and dependency and the cultural
narratives which incline people towards staying positive,
trying everything and trusting in the ‘experts’ [13, 38].
Limitations and implications for further research
The main limitation of this study was the lower than
intended number of participants recruited, which was due
to the closure of the FRAGMATIC trial, and the high rate
of attrition common to research involving this patient
group. The amount and quality of data collected in the
interviews, and the in-depth approach to analysis using
IPA, meant that in most parts the research still generated
strong results, although several notes of caution need to
be issued.
First, we captured only the range of experiences of those
well enough to speak with us at follow-up interviews. The
high rate of attrition due to deterioration and death sug-
gests that we may have missed at follow-up those patients
who experienced the most severe decline in their health,
intensification of symptoms and more negative experi-
ences. The views and experiences reported here are also
nearly all those of male participants, meaning that it is not
Harrop et al. Trials  (2016) 17:329 Page 9 of 12
possible to draw conclusions about female experiences or
to explore any differences between our male and female
participants. The low number of intervention participants
similarly limits the conclusions that can be drawn about
patients’ experiences of injecting dalteparin over time.
Out of an initial sample of four, two withdrew after the
first interview and only one participant completed all
three interviews. If possible, research involving further
interviews with patients receiving this treatment is recom-
mended. The extremely low entry of female participants
into the study and the smaller number of intervention
participants was determined by the characteristics of par-
ticipants entering the FRAGMATIC trial at our three sites
in this period (only one person declined to participate in
the sub-study). Had the qualitative study opened earlier
and at more sites, higher numbers of participants could
have been recruited, and we might have been able to equal
obtain equal or closer to closer to equal numbers of male/
female and control/intervention participants.
A further limitation in our study design was that we were
unable to interview patients prior to randomisation. As
already discussed, our data demonstrated clear differences
between intervention and control participants in terms of
their reasons for taking part in the trial and degree of
reflection on the trial, which we suggest might be explained
in terms of a post-randomisation process of rationalization
amongst control participants. Future longitudinal studies
should aim to interview patients prior to randomisation, as
this would enable a more rigorous investigation of how atti-
tudes shift pre- and post-treatment allocation. Given our
findings on patient misunderstandings and clinician influ-
ences on patient decision-making, it would also be helpful
in future research to analyse patient-professional interac-
tions and the information-giving approaches of trial staff in
trial-related consultations.
Finally, it is worth noting that many of these limiting
factors could have been addressed if the qualitative
study had been incorporated into the main trial from
its inception, as in some of our other studies. In these
‘embedded’ studies, investigation of patient experience
is included as a stated secondary outcome in the main
trial, and the qualitative researchers also are members of
the Trial Management Group. This helps to give greater
status to the qualitative work and, where appropriate, also
enables changes to the trial to be recommended on the
basis of these insights [8, 10, 21]. A recently conducted
synthesis of findings from this portfolio of work is to be
published shortly and will help to further unravel and
affirm the trial experiences of participants with cancer and
other advanced illnesses.
Conclusions
Participation in the FRAGMATIC trial was viewed
positively by nearly all participants, with apparent
psychological, emotional and social benefits reported in
the control and intervention groups. One implication
of these results, therefore, is that clinical trials should
be offered to patients with advanced cancer and that
non-placebo designs, whilst not ideal, can be acceptable
to participants who are able to find reasons other than
hope of medical benefit for participating in trials,
mainly altruism. However, the generally poor levels of
understanding of trial purpose and processes for some
patients, combined with an apparent tendency towards
therapeutic misconception and limited engagement
with trial information, suggest a need to improve
information-giving and consent processes.
Trial staff need to recognize and try to counter the in-
fluence that they ‘naturally’ have on patient decisions
[19], and likewise the expectations that patients have for
treatment decisions which are determined by expert as-
sessment as opposed to the ‘chance’ inherent in random
allocation. Finding ways of better explaining clinical un-
certainty, principles of random selection and laying em-
phasis on the fact that clinical tests and/or assessments
are not used to determine treatment allocation could
help [7]. Delivering such messages more informally, at
times which are meaningful for patients, and without
overloading patients with written information might also
be steps in the right direction. Checking patient under-
standing and motivations at the time of consent and
later intervals could also help improve how ‘informed’
patient consent in trials really is [9]. Increased public
awareness of the general purpose and process of trial
participation could also help to improve patient under-
standing in the longer term [4] whilst also addressing
problems of information overload.
In terms of implications for patient care in clinical prac-
tice, daily injections of dalteparin were acceptable to our
participants because of the perceived potential benefits.
Whilst no survival benefit was observed in the dalteparin
arm, there was significant reduction in the risk of venous
thromboembolism and no difference in major bleeding
events [25]. As such, this research may support the use of
dalteparin in clinical practice with patients with advanced
lung cancer, although further interviews would definitely
be needed to confirm this, given our low number of inter-
vention group participants. Our research also highlighted
the salience of good communication, friendly clinic envi-
ronments and positive relationships with clinical staff for
patient well-being, factors which should not be neglected
in the planning and delivery of health and social care ser-
vices for patients with advanced illness.
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